Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial
Crossref DOI link: https://doi.org/10.1007/s40121-016-0110-5
Published Online: 2016-05-26
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ferenci, Peter
Caruntu, Florin A.
Lengyel, Gabriella
Messinger, Diethelm
Bakalos, Georgios
Flisiak, Robert
Funding for this research was provided by:
F Hoffmann-La Roche